engleski

Left ventricular ejection fractions in HER2- positive breast cancer patients undergoing trastuzumab treatment

Trastuzumab (TZB) is a recombinant humanized monoclonal antibody, used for the treatment of human epidermal growth factor receptor 2 (HER2) positive breast cancer. Cardiotoxicity is an important side effect of TZB therapy, which manifests mainly as a decrease in left ventricular ejection fraction (LVEF). The aim of this study was to assess the cardiac safety during TZB treatment and investigate the possible influence of other therapy options on trastuzumab-related cardiotoxicity.

Breast cancer ; Cardiotoxicity ; Human epidermal growth factor receptor 2 ; Trastuzumab ; Ventricular ejection fraction

nije evidentirano